Related Experiment Video

Updated: Jun 18, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor

Lodovica Zullo1,2, Elora Castanet3, Zineb Maaradji4

  • 1Department of Cancer Medicine, Thoracic Cancer Unit, Gustave Roussy, Villejuif, France.

JCO Precision Oncology
|August 1, 2024
PubMed

Insights

We present two cases of small cell lung cancer (SCLC) with EGFR exon20 insertions. These patients were treated with amivantamab and tyrosine kinase inhibitors (TKIs).

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Small cell lung cancer (SCLC) is an aggressive malignancy.
  • Epidermal growth factor receptor (EGFR) mutations are common in lung cancer.
  • EGFR exon20 insertions are a specific subset of mutations often resistant to standard therapies.

Observation:

  • Two cases of SCLC with confirmed EGFR exon20 insertions were identified.
  • These patients received treatment targeting the specific EGFR mutation.

Findings:

  • The study details the treatment of two SCLC patients with EGFR exon20 insertions.
  • Treatment involved amivantamab, an EGFR-specific antibody, and tyrosine kinase inhibitors (TKIs).

Implications:

  • This report highlights the potential of targeted therapies for SCLC with EGFR exon20ins.
  • Amivantamab and TKIs may offer new treatment avenues for this rare SCLC subtype.
  • Further research is warranted to explore efficacy and expand treatment options.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K